PPT-The Challenge of Fentanyl in Buprenorphine Treatment

Kaylin A Klie MD MA FASAM Addiction Medicine University of Colorado and Denver Health ICWB Shared Learning March 28 th 2022 Discussion Today Low Dose Buprenorphine Initiation Strategies. Kylie Reed . a,b. ,. Karolina . Bogdanowicz. . b, . James Bell . a,b. , . Rob . VanderWaal. . a, . Jenny Keen . a,b. , . Pete . Beavan. . a. , Shelagh Baillie . c, . Alastair Knight . d, . John . John Arthur Muenz, Jr., M.D., FAAPM&R, FABAM, FAAFP. Family Care Partners. jmuenz@familycarepartners.com. Disclosure. I have no actual or potential conflict of interest in relation to this . program/presentation.. M.Ed. Pharmacokinetics. Speed of onset is faster with increased lipid solubility. Morphine:. Relatively low lipid solubility. Only 10-20% un-ionized at physiologic pH so doesn’t diffuse into tissues quickly. Riding The Waves of Change. VSIAS Conference . April Ashworth, MSN, AGPCNP-BC. Objectives. . Discuss the timeline of the current opioid epidemic with its devastating consequences. Discuss acute and chronic pain with updated guidelines. Molly Rutherford, MD. Family Physician. Bluegrass Family Wellness. Crestwood, KY. I have no commercial interests to disclose. Learning Objectives. Review the ASAM decision making guidelines. Explain how to obtain a DEA waiver. Treatment (MAT):. Problem . or Solution?. Quintin Thomas Chipley, M.A., M.D., Ph.D.. a. nd. Greg Jones, M.D., ABFM, ABAM, MRO. Prepared for CAPTASA 2016. DISCLOSURES. Neither presenter has any financial interest in any mode of treatment as discussed in this presentation.. Medication Assisted Treatment For Opioid Use Disorders Shannon Allen, MD Jade Wellness Center July 19, 2018 Rates of Relapse in Opioid Use Disorders are High Benefits of Medication Assisted Treatments Policy: Buprenorphine Medical Policy No. 65 . 20 . 00.10 Last Updated 01 / 26 / 20 2 1 1 Medication Treatment Guidelines Disorders (SUDs) - Transmucosal Buprenorphine Medical p olicy n o. Julie Kmiec, DO. Assistant Professor of Psychiatry. University of Pittsburgh. kmiecj@upmc.edu. April 10, 2018. 1. Objectives. Review prevalence of opioid use disorders. Discuss the unmet needs for those with OUD. Therapy. Opioids. and HIV. You may know that…. Injection drug use (IDU), either directly or via sexual contact with an IDU partner, accounts for one-third of the cumulative estimated AIDS cases in the U.S.. As illicit fentanyl has become a predominant opioid of abuse in New Mexico and many areas of the United States. Buprenorphine induction is becoming more difficult with women having trouble tolerating the withdrawal required to initiate buprenorphine and then having prolonged withdrawal despite buprenorphine titration. I. E. DUCATION. 1. HIGH RISK MEDICINES. Education delivered by:. Date of education: . Objectives. Provide a brief overview of opioid skin patches currently available. . Describe recognised safety issues. William J. Lorman, JD, PhD, MSN, PMHNP-BC, CARN-AP. V. P. & Chief Clinical Officer, Livengrin Foundation, Inc.. Ass’t. Clinical Professor, Doctoral Nursing Dept., . Drexel University. wlorman@livengrin.org. Patient Assessmen • Establishment of a diagnosis of Opioid Use Disorder (OUD). • Discussion of current opioid use. • Evaluation of patient’s readiness to participate. • Ph